Request Demo
Last update 23 Aug 2025
Rulonilimab
Last update 23 Aug 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Lonelizumab, Recombinant humanized anti-PD-1 monoclonal antibody(Shandong New Time Pharmaceutical Co. Ltd.), 重组人源化抗PD-1单抗 (山东新时代药业) + [3] |
Target |
Action inhibitors, stimulants |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 453107141H
Source: *****
Sequence Code 453107142L
Source: *****
Related
14
Clinical Trials associated with RulonilimabNCT06755515
A Phase Ⅱ/Ⅲ Randomized, Double-Blind, Placebo-Controlled Trial of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
CTR20242664
评价洛奈利单抗联合含铂化疗±贝伐珠单抗一线治疗晚期、持续、复发/转移性宫颈癌患者的有效性和安全性的多中心、随机、双盲、安慰剂对照的II/III期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II/III clinical study to evaluate the efficacy and safety of lonerizumab combined with platinum-containing chemotherapy ± bevacizumab as first-line treatment for patients with advanced, persistent, recurrent/metastatic cervical cancer
CTR20230474
评价洛奈利单抗联合化疗一线治疗晚期或转移性非小细胞肺癌（NSCLC）的有效性和安全性的单臂、开放、多中心II期临床研究
[Translation] A single-arm, open-label, multicenter phase II clinical study to evaluate the efficacy and safety of lonerimab combined with chemotherapy as the first-line treatment for advanced or metastatic non-small cell lung cancer (NSCLC)
100 Clinical Results associated with Rulonilimab
Login to view more data
100 Translational Medicine associated with Rulonilimab
Login to view more data
100 Patents (Medical) associated with Rulonilimab
Login to view more data
100 Deals associated with Rulonilimab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Cervical Carcinoma | Phase 3 | China | 26 Sep 2024 | |
| Metastatic Carcinoma to the Uterine Cervix | Phase 3 | China | 26 Sep 2024 | |
| Unresectable Hepatocellular Carcinoma | Phase 3 | China | 11 Nov 2022 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 12 May 2023 | |
| metastatic non-small cell lung cancer | Phase 2 | China | 12 May 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 23 May 2022 | |
| Diffuse Large B-Cell Lymphoma | Phase 2 | China | 11 Apr 2022 | |
| CD20 positive Diffuse Large B-Cell Lymphoma | Phase 2 | - | 01 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 2 | - | 01 Jan 2022 | |
| Primary Central Nervous System Lymphoma | Phase 2 | China | 18 May 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free